Barr Wins Patent Challenge Vs. Ferring, Aventis

Law360, New York (February 9, 2005, 12:00 AM EST) -- Barr Laboratories, Inc. has won a patent challenge to the antidiuretic replacement therapy DDAVP (Desmopressin Acetate), a drug made by Ferring B.V. and Aventis Pharmaceuticals, Inc.

A judge with the U.S. District Court for the Southern District of New York granted summary judgment in Barr's challenge to the patents for DDAVP tablets, 0.1 mg and 0.2 mg, the company said.

The court ruled that the patents alleged to cover DDAVP are unenforceable and not infringed by Barr's product, according to Barr.

The court's decision effectively ends...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.